- Conditions
- Herpes Simplex, HIV Infections, Herpes Genitalis
- Interventions
- Valacyclovir hydrochloride
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 20
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1945–1968
of 2,291
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 6,100 participants
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Subjects
- Interventions
- fosamprenavir + ritonavir + methadone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Buffalo, New York
- Conditions
- Hepatitis C Virus Genotype-1
- Interventions
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- HIV Infections
- Interventions
- EP1090
- Biological
- Lead sponsor
- Epimmune
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- West Hollywood, California • Denver, Colorado
- Conditions
- HIV Infections
- Interventions
- Bronchoalveolar lavage
- Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- HIV Infections
- Interventions
- Trichosanthin, Zidovudine
- Drug
- Lead sponsor
- Genelabs Technologies
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Tampa, Florida + 2 more
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
- Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- HIV Infections
- Interventions
- Kaletra + Current Dual NRTI Backbone, Current Regimen
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV
- Interventions
- Atazanavir Sulphate, Ritonavir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 3 Months to 11 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Syracuse, New York
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Foscarnet sodium
- Drug
- Lead sponsor
- Astra USA
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections, AIDS
- Interventions
- efavirenz, stavudine extended release, lamivudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 10
- States / cities
- Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
- Conditions
- HIV Infections
- Interventions
- p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- Morris Plains, New Jersey
- Conditions
- HIV Infections
- Interventions
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1997
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Lymphoma, Non-Hodgkin, HIV Infections
- Interventions
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 22
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
- Conditions
- HIV Infections
- Interventions
- Emtricitabine, Lamivudine
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- St. Petersburg, Florida • Great Neck, New York